pbm pharmacy-benefit-managers optumrx cvs-caremark express-scripts unitedhealth cigna drug-pricing rebates class-analysis follow-the-money
related: UnitedHealth Group - Optum · Blue Shield of California · Anthem - Elevance Health · PhRMA
PBM Industry Bloc. OptumRx, CVS Caremark, Express Scripts
Money
Three pharmacy benefit managers control 80% of the U.S. prescription drug market. OptumRx (owned by UnitedHealth Group). CVS Caremark (owned by CVS Health). Express Scripts (owned by Cigna). They negotiate drug prices between pharmaceutical manufacturers and pharmacies, extracting profit through opaque rebate structures that are not disclosed to consumers, employers, or often even the health plans that hire them. The FTC found in a 2024 report that PBM rebate practices inflated insulin prices and steered patients toward higher cost drugs that generated larger rebates. Both Trump and Newsom attacked PBMs in public. Both preserved the PBM profit model in policy. Trump’s 2024 executive order targeting PBMs produced no structural reform. Newsom vetoed AB 2200 (PBM price transparency) in 2022, reversed under pressure, and signed SB 41 in 2025 with provisions that do not take effect until 2027. The PBM industry donates across party lines and receives protection from both.
The Three Companies
| PBM | Parent Company | Market Share | Revenue |
|---|---|---|---|
| OptumRx | UnitedHealth Group | ~29% | Part of Optum’s $227B revenue (2023) |
| CVS Caremark | CVS Health | ~26% | Part of CVS’s $357B revenue (2023) |
| Express Scripts | Cigna Group | ~25% | Part of Cigna’s $195B revenue (2023) |
Combined market share exceeds 80% of all prescription drug transactions in the United States.
The Rebate Model. How the Money Flows
PBMs negotiate rebates from drug manufacturers in exchange for placing their drugs on formulary (the list of covered drugs). The rebates are not passed through to patients at the point of sale. Patients pay based on the list price, not the net price after rebate. The PBM retains a portion of the rebate as profit.
This structure incentivizes PBMs to prefer higher priced drugs with larger rebates over lower priced alternatives. A drug priced at $300 with a $100 rebate generates more PBM revenue than a drug priced at $100 with no rebate, even though the net cost to the system is the same.
The FTC documented this pattern extensively in its 2024 interim report on PBM practices, specifically in the insulin market where three manufacturers (Eli Lilly, Novo Nordisk, Sanofi) and three PBMs created a pricing spiral that tripled insulin costs for patients over a decade.
Both Sides Protection
| Politician | Anti PBM Rhetoric | Pro PBM Policy |
|---|---|---|
| Trump | 2024 executive order targeting PBMs | No structural reform enacted |
| Newsom | Signed CalRx generic insulin program | Vetoed AB 2200 (PBM transparency, 2022). SB 41 delayed until 2027 |
The PBM industry’s bipartisan protection is the clearest example of donor class structural power overriding rhetorical opposition. Both parties attack PBMs for political advantage. Neither party enacts the transparency requirements that would expose the rebate model.
Sources
research-status:: ready — 80% market share, FTC 2024 report, rebate model documented, both-sides protection table, OptumRx/CVS Caremark/Express Scripts. 3 sources, Tier 1. All headers. Promoted Session 38m. content-readiness:: ready